|
|
| Line 1: |
Line 1: |
| | _NOTOC__ |
| {{CMG}} | | {{CMG}} |
| {{Prostate cancer}} | | {{Prostate cancer}} |
| | ==Overview== |
|
| |
|
| ==Methods of Diagnosis== | | ==Laboratory findings== |
| ===Tumor markers===
| |
| {{main|Tumor markers}}
| |
| Tissue samples can be stained for the presence of PSA and other tumor markers in order to determine the origin of maligant cells that have metastasized.<ref name="pmid17667550">{{cite journal |author=Chuang AY, Demarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI |title=Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma |journal= The American Journal of Surgical Pathology|volume=31 |issue=8 |pages=1246–1255 |year=2007 |pmid=17667550 |doi=10.1097/PAS.0b013e31802f5d33}}</ref>
| |
|
| |
|
| ===New tests being investigated===
| | * Serum [[prostate-specific antigen]] (PSA) level |
| Currently, an active area of research involves non-invasive methods of prostate tumor detection. Adenoviruses modified to transfect tumor cells with harmless yet distinct genes (such as luciferase) have proven capable of early detection. So far, though, this area of research has only been tested in animal and [[LNCaP]] models.<ref>Iyer M, Salazar FB, Lewis X, Zhang L, Wu L, Carey M and Gambhir SS. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transg Res.2005; 14(1): 47–55</ref>
| |
|
| |
|
| ===PCA3===
| |
| Another potential non-invasive method of early prostate tumor detection is through a molecular test that detects the presence of cell-associated PCA3 mRNA in urine. PCA3 mRNA is expressed almost exclusively by prostate cells and has been shown to be highly over-expressed in prostate cancer cells. PCA3 is not a replacement for PSA but an additional tool to help decide if, in men suspected of having prostate cancer, a biopsy is really needed. The higher the expression of PCA3 in urine, the greater the likelihood of a positive biopsy, i.e. the presence of cancer cells in the prostate. Company [http://www.diagnocure.com/en/products-projects/prostate-cancer/prostate-cancer.php Diagnocure] has an exclusive worldwide license for all diagnostic and therapeutic applications related to PCA3
| |
|
| |
| ===Early prostate cancer===
| |
| It was reported in April 2007 that a new blood test for [[early prostate cancer antigen-2]] (EPCA-2) is being researched that may alert men if they have prostate cancer and how aggressive it will be.<ref>[http://www.msnbc.msn.com/id/18328032/site/newsweek/ A Prostate Cancer Revolution]. Newsweek, April 26, 2007.</ref><ref name="pmid17437801">{{cite journal |author=Hansel DE, DeMarzo AM, Platz EA, ''et al'' |title=Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies |journal=J. Urol. |volume=177 |issue=5 |pages=1736–40 |year=2007 |pmid=17437801 |doi=10.1016/j.juro.2007.01.013}}</ref>
| |
|
| |
| ===Prostasomes===
| |
| Epithelial cells of the prostate secrete [[prostasomes]] as well as [[Prostate specific antigen|PSA]]. Prostasomes are membrane –surrounded, prostate-derived organelles that appear extracellularly and one of their physiological functions is to protect the sperm from attacks by the female immune system. Cancerous prostate cells continue to synthesize and secrete prostasomes and may be shielded against immunological attacks by these prostasomes. Research of several aspects of prostasomal involvement in prostate cancer has been performed.<ref>Ronquist G, Carlsson L, Larsson A, Nilsson BO: "Prostasomes: Proceedings from a symposium held at the Wenner-Gren Centre, Stockholm, June 2001" pp. 1-9. Portland Press , London
| |
| </ref>
| |
|
| |
| ===Prostate mapping===
| |
| Prostate Mapping is a new diagnostic process developed by urology and radiology consultants in the UK. This is a method of diagnosis which may be accurate in determining the precise location and aggressiveness of cancer. It uses a combination of multi-sequence MRI imaging techniques and a template guided biopsy system and involves taking multiple biopsies through the skin that lies in front of the back passage rather than through the back passage. The procedure is carried out under [[general anesthetic]].
| |
|
| |
|
| ==References== | | ==References== |